人才隊伍
返回列表
雷曉波
個人簡介
中國醫學科學院北京協和醫學院病原生物學研究所研究員，博士生導師。主要從事呼吸道病毒與宿主相互作用機制及其感染致病機制的研究。主持國家傳染病重大專項和國家自然科學基金面上項目等多項國家級科研項目。在Nat Commun、Signal Transduct Target Ther、Cell Rep、PLoS Pathog、J Biol Chem、J Virol、Natl Sci Rev和FASEB J等SCI收錄雜志上發表SCI論文24篇。入選2020年Springer Nature中國學者年度高影響力研究，2022年斯坦福大學全球前2%頂尖科學家榜單。目前擔任中國微生物學會病毒學專業委員會委員和中華預防醫學會醫學病毒學分會青年小組委員。
研究方向
重要呼吸道病毒與宿主相互作用研究
科研項目
1. 國家自然科學基金面上項目，GSDME介導的細胞焦亡在腸道病毒71型感染致病機制中的作用研究，81971948，課題負責人；
2. 國家傳染病重大專項，基于人類全基因組編碼及非編碼區高通量篩選的抗病毒靶標發現新技術研究，ZX201810301401，課題負責人；
3. 國家自然科學基金面上項目，高爾基體ACBD3蛋白復合物參與EV71復制的分子機制研究，81672032，課題負責人；
4. 中國醫學科學院醫學與健康科技創新工程，抗感染藥物/疫苗快速評測與開發，2016-I2M-1-005，子課題負責人；
5. 國家重點研發計劃，新型冠狀病毒感染復制關鍵宿主因子及其作用機制研究，2020YFA0707600，課題骨干；
6. 國家自然科學基金重點項目，重要腸道病毒感染復制關鍵宿主因子全景式篩選及其作用分子機制研究，81930063，2020.01-2024.12，課題骨干。
研究成果
代表性論文：(# 共同第一作者；* 共同通訊作者)
1. Zhang D#, Qiao L#, Lei X#, Dong X, Tong Y, Wang J*, Wang Z*, Zhou R*. Mutagenesis and structural studies reveal the basis for the specific binding of SARS- CoV-2 SL3 RNA element with human TIA1 protein. Nat Commun. 2023 Jun 22; 14(1):3715.
2. Wu Z#, Lei X#, Wang X#, Zhang Z, Li Y, Gao L, Liang X, Wang P, Wang J*, Ma C*. Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection. Signal Transduct Target Ther. 2023 Jan 18;8(1):19.
3. Guo S#, Lei X#, Chang Y#, Zhao J#, Wang J#, Dong X, Liu Q, Zhang Z, Wang L, Yi D, Ma L, Li Q, Zhang Y, Ding J, Liang C, Li X, Guo F*, Wang J*, Cen S*. SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis. Signal Transduct Target Ther. 2022 Dec 27;7(1):400.
4. Dong S#, Shi Y#, Dong X, Xiao X, Qi J, Ren L, Xiang Z, Zhou Z, Wang J*, Lei X*. Gasdermin E is required for induction of pyroptosis and severe disease during enterovirus 71 infection. J Biol Chem. 2022 May; 298(5): 101850.
5. Zhou Z#, Zhang X#, Lei X#, Xiao X#, Jiao T, Ma R, Dong X, Jiang Q, Wang W, Shi Y, Zheng T, Rao J, Xiang Z, Ren L, Deng T, Jiang Z, Dou Z, Wei W*, Wang J*. Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection. Signal Transduct Target Ther. 2021 Nov 3; 6(1):382.
6. Wang W#, Zhou Z#, Xiao X#, Tian Z, Dong X, Wang C, Li L, Ren L, Lei X*, Xiang Z*, Wang J*. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell Mol Immunol. 2021,18(4):945-953.
7. Lei X#, Dong X#, Ma R#, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L, Guo F, Zhao Z, Zhou Z*, Xiang Z*, Wang J*. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun, 2020, 11(1): 3810.
8. Lei X#, Zhang Z#, Xiao X, Qi J, He B*, Wang J*. Enterovirus 71 Inhibits Pyroptosis through Cleavage of Gasdermin D. J Virol. 2017, 91(18): e01069-17.
9. Xiao X#, Lei X#, Zhang Z, Ma Y, Qi J,Wu C, Xiao Y, Li L, He B*, Wang J*. Enterovirus 3A facilitates viral replication by promoting Phosphatidylinositol4-kinaseIIIβ-ACBD3 interaction. J Virol. 2017, 91(19): e00791-17.
10. Wang H#, Lei X#, Xiao X, Yang C, Lu W, Huang Z, Leng Q, Jin Q, He B, Meng G*, Wang J*. Reciprocal Regulation between Enterovirus 71 and the NLRP3 Inflammasome. Cell Rep. 2015, 12(1): 42-48.
11. Lei X#, Cui Sheng, Zhao Z*, Wang J*. Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth disease. Natl Sci Rev. 2015, 2 (3): 268-284.
12. Lei X#, Han N#, Xiao X, Jin Q*, He B*, Wang J*. Enterovirus 71 3C inhibits cytokine expression through cleavage of the TAK1/TAB1/TAB2/TAB3 complex. J Virol. 2014, 88(17): 9830-9841.
13. Lei X, Xiao X，Xue Q，Jin Q*, He B*, Wang J*. Cleavage of Interferon Regulatory Factor 7 by Enterovirus 71 3C Suppresses Cellular Responses. J Virol. 2013，87（3）：1690-1698.
14. Lei X#, Sun Z#, Liu X, Jin Q*, He B*, Wang J*.Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3，J Virol. 2011，85（17）：8811-8818.
15. Lei X, Liu X, Ma Y, Sun Z, Yang Y, Jin Q*, He B*, Wang J*. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol. 2010, 84(16): 8051-8061.
研究生培養
團隊累計培養研究生、博士后10人次